TABLE 3—

Effect of Race on Endocrine Therapy Use Among Eligible Included Studies

First Author	Outcome	Disparity	Data Source	Population (% African American)
Partridge19	Adherence	White > non-White	Pharmacy claims	NJ Medicaid and NJ PAAD program (17%a)
Riley22	Adherence	White > African Americanb	Pharmacy claims	Medicare (6%)
Kimmick60	Initiation	No significant association	Pharmacy claims	NC Medicaid (41%a)
	Persistence	No significant association
	Adherence	No significant association
Liu81	Persistence	Less acculturated Hispanic > White	Self-report	CA Medicaid: CA Breast and Cervical Cancer Treatment Program (6%)
Livaudais82	Initiation	NHW > Hispanic, NHW > Chinese	Pharmacy claims	KPNC (6%)
Livaudais84	Initiation	Asian > NHW, African Americanc	Self-report	NCBCF (11%)
Livaudais83	Initiation, persistence	No significant association	Self-report	WHI study (4%)
Wheeler87	Initiation	No significant association	Pharmacy claims	NC Medicaid (53%a)
Bhatta78	Adherence	No significant association	Self-report	University of Chicago Hospital (31.5%)
	Persistence		Self-report and medical record review
	Compliance
Reeder-Hayes85	Initiation	White > African American	Pharmacy claims	Privately insured (11%)
Friese80	Initiation	African American and Latina > White	Self-report	LA County and metropolitan Detroit SEER regions (14.2%)
	Persistence	No significant association
Bickell79	Initiation	White > Black, Hispanic	Medical record review	6 NYC hospitals (21%)

Note. CA = California; LA = Los Angeles; NC = North Carolina; NHW = Non-Hispanic White; NJ = New Jersey; KPNC = Kaiser Permanente of Northern California; NCBCF = Northern California Breast Cancer Family Registry; NYC = New York City; PAAD = Pharmaceutical Assistance to the Aged and Disabled; SEER = Surveillance, Epidemiology, and End Results; WHI = Women’s Health Initiative.

^a% non-White.

^bOnly among women without the low-income subsidy.

^cOnly among women with suspected hereditary breast cancer.